Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Qvents is managed by experienced Pharma industry professionals. Qvents team has several years of experience in the industry in GMP, Quality and Technical Operations. Experience in establishing systems, processes and controls; handling regulatory audits and responses, observations, remediation and mitigation plans; Handling various Quality events (Deviations, OOS, Complaints, Recalls).
Qvents team carefully select the topics of discussion and posts in the Qvents portal; Picks the most relevant news, learning resources, list of guidelines which will be useful for Pharma professionals.
Qvents team moderate the discussions and comments, ensure the discussions and comments are relevant, clean and unbiased.
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June – July 2025. The inspection, conducted by USFDA investigators Joohi Castelvetere, Robert J.Ham, Martin M.Kimani and Shannon L.Maisano resulted in a USFDA Form 483 with...
USFDA has approved Insmed’s Brinsupri (Brensocatib) for Bronchiectasis, a chronic drug disease. The medicinal product will be available as 10 and 25mg once daily tablets.  In a press release Insmed’s claimed that Brinsupri is the first and only treatment...
In a blog posted on 8 August 2025, MHRA’s Chris Jones (IAG Chair) and Himal Makwana (Head of DMRC) elaborates actions UK licence holders should take following issuance of USFDA Warning Letters to their supply chain partners. UK licence holders who...
Qvents.in is owned and operated by Tejoh Business Solutions LLP, India.
Qvents.in is a Pharma GMP portal, a Digital Pharma TechOps platform, Knowledge portal for Pharma TechOps professionals. A platform for Pharma TechOps professionals to gets news and updates on Pharma GMP events.
Qvents is managed by experienced Pharma industry professionals with several years of experience in the industry in GMP, Quality and Technical Operations, Regulatory filings and approvals.
At Qvents we are continuously updating the features and content of the portal with the objective of a Wholesome Learning, Knowledge, Information, Resources & Networking platform for Pharma professionals. Qvents team picks the most relevant Pharma TechOps news, Quality and Regulatory events, collates most important guidelines and technical resources, trainings & webinars for our audience.
Qvents.in is owned and operated by Tejoh Business Solutions LLP, India.
Qvents.in is a Pharma GMP portal, a Digital Pharma TechOps platform, Knowledge portal for Pharma TechOps professionals. A platform for Pharma TechOps professionals to gets news and updates on Pharma GMP events.
Qvents discussion Forums for you to network and connect with Industry peers, to discuss Technical and GMP topics, Issues, Audit observations and auditor focus, CAPAs and Remediation actions. Qvents portal lists Pharma Guidelines organised topic wise for you to find all related guidelines on each topic at one place. Qvents Learning Resources page lists select technical trainings, webinars, seminars on various topics. Qvents list Upcoming Trainings for users to register for trainings, Training Archives of past events for users view past events. Qvents Pharma Jobs page list Pharma Job openings for Techops professionals. Employers and Recruiters can list the Job openings with Qvents.
Qvents is managed by experienced Pharma industry professionals with several years of experience in the industry in GMP, Quality and Technical Operations, Regulatory filings and approvals.
At Qvents we are continuously updating the features and content of the portal with the objective of a Wholesome Learning, Knowledge, Information, Resources & Networking platform for Pharma professionals. Qvents team picks the most relevant Pharma TechOps news, Quality and Regulatory events, collates most important guidelines and technical resources, trainings & webinars for our audience.
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June – July 2025. The inspection, conducted by USFDA investigators Joohi Castelvetere, Robert J.Ham, Martin M.Kimani and Shannon L.Maisano resulted in a USFDA Form 483 with...
USFDA has approved Insmed’s Brinsupri (Brensocatib) for Bronchiectasis, a chronic drug disease. The medicinal product will be available as 10 and 25mg once daily tablets.  In a press release Insmed’s claimed that Brinsupri is the first and only treatment...
In a blog posted on 8 August 2025, MHRA’s Chris Jones (IAG Chair) and Himal Makwana (Head of DMRC) elaborates actions UK licence holders should take following issuance of USFDA Warning Letters to their supply chain partners. UK licence holders who...
